administering an additional therapeutic agent to the individual. In some such embodiments, the additional therapeutic agent comprises an antibody that binds CD22. In some embodiments, the additional therapeutic agent is an immunoconjugate comprising an antibody that binds CD22 covalently attached to a cytotoxic agent.

[0017a] In one aspect, there is provided the use of the immunoconjugate as described herein in the manufacture of a medicament for the inhibition of proliferation of a CD79b-positive cell in a condition characterized by unregulated cell growth or proliferation, ~~wherein the cell is to be exposed to the immunoconjugate~~ under conditions permissive for binding of the immunoconjugate to CD79b on the surface of the cell, thereby inhibiting proliferation of the cell.

[018] In one aspect, there is provided an *in vitro* method of inhibiting proliferation of a CD79b-positive cell, the method comprising exposing the cell to the immunoconjugate described herein under conditions permissive for binding of the immunoconjugate to CD79b on the surface of the cell, thereby inhibiting proliferation of the cell. In some embodiments, the cell is a neoplastic B cell. In some embodiments, the cell is a lymphoma cell.

BRIEF DESCRIPTION OF THE FIGURES

[019] **Figures 1A-1B** show the amino acid sequence of the heavy chain variable region of murine anti-CD79b antibody MA79b aligned with the humanized MA79b graft and humanized versions 17, 18, 28, and 32 (huMA79b graft, huMA79bv17, huMA79bv18, huMA79bv28, and huMA79bv32, respectively), and aligned with the human subgroup III sequence. The HVRs are boxed (HVR-H1, HVR-H2, HVR-H3). The sequences bracketing the HVRs are the framework sequences (FR-H1 to FR-H4). The sequences are numbered according to Kabat numbering. The Kabat, Chothia, and contact CDRs are indicated about the boxed HVRs.

[020] **Figures 2A-2B** show the amino acid sequence of the light chain variable region of murine anti-CD79b antibody MA79b aligned with the humanized MA79b graft and humanized versions 17, 18, 28, and 32 (huMA79b graft, huMA79bv17, huMA79bv18, huMA79bv28, and huMA79bv32, respectively), and aligned with the human subgroup kappa I sequence. The HVRs are boxed. The FR-L1, FR-L2, FR-L3, and FR-L4 sequences bracket the HVRs (HVR-L1, HVR-L2, HVR-L3). The sequences are numbered according to Kabat numbering. The Kabat, Chothia, and contact CDRs are indicated about the boxed HVRs.

[021] **Figure 3** shows the full length amino acid sequences (variable and constant regions) of the light and heavy chains of humanized anti-CD79b antibody huMA79bv28, isotype IgG1. The underlined portions are the constant domains.

WHAT IS CLAIMED IS:

1. An immunoconjugate comprising an antibody that binds CD79b covalently attached to a cytotoxic agent, wherein the antibody that binds CD79b comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 21, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 22, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23; and wherein the cytotoxic agent is a pyrrolobenzodiazepine.

2. The immunoconjugate of claim 1, wherein the antibody further comprises (i) HVR-L1 comprising an amino acid sequence selected from SEQ ID NOs: 18, 24, and 35, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 25, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 26.

3. The immunoconjugate of claim 2, wherein the antibody comprises HVR-L1 comprising the amino acid sequence of SEQ ID NO: 24.

4. The immunoconjugate of any one of claims 1 to 3, wherein the antibody comprises:

a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 11; or

b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 12; or

c) a VH sequence as in (a) and a VL sequence as in (b).

5. The immunoconjugate of any one of claims 1 to 4, comprising a VH sequence having an amino acid sequence selected from SEQ ID NOs: ~~7,~~ 9, 11, and 13.

6. The immunoconjugate of claim 5, comprising a VH sequence having the amino acid sequence of SEQ ID NO: 11.

7. The immunoconjugate of any one of claims 1 to 6, comprising a VL sequence having an amino acid sequence selected from SEQ ID NOs: 8, 10, 12, and 14.

8. The immunoconjugate of claim 7, comprising a VL sequence having the amino acid sequence of SEQ ID NO: 12.

9. An immunoconjugate comprising an antibody that binds CD79b covalently attached to a cytotoxic agent, wherein the antibody comprises (a) a VH sequence having the amino acid sequence of SEQ ID NO: 11 and a VL sequence having the amino acid sequence of SEQ ID NO: 12, and wherein the cytotoxic agent is a pyrrolobenzodiazepine.

10. The immunoconjugate of any one of claims 1 to 9, wherein the antibody is an IgG1, IgG2a or IgG2b antibody.

11. An immunoconjugate of any one of claims 1 to 10, wherein the immunoconjugate has the formula Ab-(L-D)p, wherein:

30. Use of the immunoconjugate of any one of claims 1 to 27 in the manufacture of a medicament for the treatment of an individual having a CD79b-positive cancer.

31. The use of claim 30, wherein the CD79b-positive cancer is selected from - lymphoma, non-Hogkins lymphoma (NHL), aggressive NHL, relapsed aggressive NHL, relapsed indolent NHL, refractory NHL, refractory indolent NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ALL), Burkitt's lymphoma, and mantle cell lymphoma.

32. The use of claim 31, wherein the immunoconjugate is to be administered with an additional therapeutic agent to the individual.

33. The use of claim 32, wherein the additional therapeutic agent comprises an antibody that binds CD22.

34. The use of claim 33, wherein the additional therapeutic agent is an immunoconjugate comprising an antibody that binds CD22 covalently attached to a cytotoxic agent.

35. Use of the immunoconjugate of any one of claims 1 to 27 in the manufacture of a medicament for the inhibition of proliferation of a CD79b-positive cell in a condition characterized by unregulated cell growth or proliferation, ~~wherein the cell is to be exposed to the immunoconjugate~~ under conditions permissive for binding of the immunoconjugate to CD79b on the surface of the cell, thereby inhibiting proliferation of the cell.

36. The use of claim 35, wherein the cell is a neoplastic B cell.

37. The use of claim 36, wherein the cell is a lymphoma cell.

38. An *in vitro* method of inhibiting proliferation of a CD79b-positive cell, the method comprising exposing the cell to the immunoconjugate of any one of claims 1 to 27 under conditions permissive for binding of the immunoconjugate to CD79b on the surface of the cell, thereby inhibiting proliferation of the cell.

39. The method of claim 38, wherein the cell is a neoplastic B cell.

40. The method of claim 39, wherein the cell is a lymphoma cell.